Unfortunately, cancer cells in general and lung cancer specifically are characterized by mutations and over activation of the PI3K-Akt-mTOR [17,18] and the Ras-MAPK [14,19] cascades that allow them to develop resistance to many first line chemotherapeutic agents highlighting the need to develop new chemotherapeutic agents. Here, MTOR is linked to cancer.